Clinical Trial Update: Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial updating osimertinib with or without savolitinib as first-line in de novo MET-positive, EGFR-mutant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Savolitinib (savolitinib)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: ACTIVE_NOT_RECRUITING